Obrixtamig
Obrixtamig is an antibody with two arms: one grabs DLL3, a protein on the surface of most neuroendocrine carcinomas, and the other grabs a T cell, pulling the killer cell onto the cancer. It is in a phase 3 trial for neuroendocrine carcinomas outside the lung.
Overview
Obrixtamig (BI 764532) is Boehringer Ingelheim's DLL3-directed T-cell engager, a class established by tarlatamab in small-cell lung cancer. DLL3 is expressed on the surface of most small-cell lung cancers and extrapulmonary neuroendocrine carcinomas but almost no normal adult tissue. It is given intravenously with step-up dosing to limit cytokine release syndrome.
The phase 2 DAREON-5 trial reported responses in DLL3-positive small-cell lung cancer and extrapulmonary neuroendocrine carcinoma, and the phase 3 DAREON-NEC-1 trial is testing obrixtamig with carboplatin and etoposide first line in DLL3-positive extrapulmonary neuroendocrine carcinoma, the first phase 3 dedicated to that disease. The extrapulmonary neuroendocrine carcinoma page names it with peluntamig and ZG006 among the DLL3 engagers in trials.
1.One arm of Obrixtamig binds DLL3 on the cancer cell.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Obrixtamig" OR ABSTRACT:"Obrixtamig" OR TITLE:"BI 764532" OR ABSTRACT:"BI 764532" OR TITLE:"BI-764532" OR ABSTRACT:"BI-764532") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Obrixtamig, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentBrigimadlin
Shares Boehringer Ingelheim and the tag subtype-drugs-wave.
- CompanyHarpoon Therapeutics
Shares DLL3, CD3, T-cell engagers (bispecific).
- CompanyJanux Therapeutics
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- TrialDAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Shares Boehringer Ingelheim, Extrapulmonary neuroendocrine carcinoma.
- TrialDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Shares Boehringer Ingelheim, Extrapulmonary neuroendocrine carcinoma.
- TrialA Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
- CompanyXencor
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
- CompanyCullinan Therapeutics
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).